August 08, 2025 a 03:43 pm
COR: Fundamental Ratio Analysis - Cencora, Inc.
Cencora, Inc., formerly AmerisourceBergen Corporation, is a key player in the pharmaceutical distribution industry. With diversified services ranging from pharmacy management to international wholesale, Cencora presents an interesting option for investors targeting the healthcare sector. Recent evaluations suggest potential growth balanced with industry-standard risks.
Fundamental Rating
Cencora, Inc.'s fundamental rating indicates a stable position with potential for growth. The following table outlines the key evaluation metrics.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 5 | |
| Return on Assets | 3 | |
| Debt to Equity | 1 | |
| Price to Earnings | 2 | |
| Price to Book | 1 |
Historical Rating
The historical analysis provides insights into Cencora's performance over time, reflecting its resilient operational framework.
| Date | Overall Score | Discounted Cash Flow | Return on Equity | Return on Assets | Debt to Equity | Price to Earnings | Price to Book |
|---|---|---|---|---|---|---|---|
| 2025-08-07 | 3 | 5 | 5 | 3 | 1 | 2 | 1 |
| Current | 3 | 5 | 5 | 3 | 1 | 2 | 1 |
Analyst Price Targets
Analysts' projections for Cencora's stock indicate limited fluctuation, suggesting stable market confidence.
| High | Low | Median | Consensus |
|---|---|---|---|
| $330 | $330 | $330 | $330 |
Analyst Sentiments
The sentiment analysis showcases a predominantly positive outlook from analysts, with 'Buy' recommendations being significant.
| Recommendation | Number | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 27 | |
| Hold | 15 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
Cencora, Inc. demonstrates solid fundamentals with significant consistency across key ratios. While the historical data reflects stability, the uniform analyst price targets and positive sentiment further underline market confidence. The primary risk lies in its dependence on healthcare industry dynamics, necessitating close monitoring of sector trends. Overall, Cencora remains a viable option for investors seeking exposure in pharmaceutical distribution.